Endo International Večkratnik prihodkov (KUV) 2024

Kaj počne Endo International?

Endo International PLC is a global pharmaceutical company based in Ireland, specializing in the development, manufacturing, and distribution of prescription medications. The company was founded in New York City in 1920 as a small narcotic business and has since undergone significant changes and expansion through mergers and acquisitions. Endo now has its headquarters in Dublin, Ireland and a diverse portfolio of prescription drugs in various therapeutic areas. The company's business model focuses on the development and marketing of innovative and generic pharmaceuticals, medical devices, and diagnostic solutions to improve global patient health. It operates in five segments: Branded Pharmaceuticals, Generics, International Pharmaceuticals, Urology, and Specialty Products. The Branded Pharmaceuticals segment includes a wide range of prescription drugs targeting various indications, including pain relievers, hormone therapies, gastrointestinal products, and oncology treatments. Some of Endo's well-known brands include Lidoderm, Voltaren, and Percocet. The Generics division produces and distributes a variety of generic medications under different brand names, utilizing synergies within its network to reduce manufacturing costs and pass savings on to customers. The International Pharmaceuticals unit is responsible for Endo's global business, maintaining partnerships and joint ventures with partners worldwide and expanding the company's portfolio into new regions and markets. The Urology segment offers a broad spectrum of products and services for urology, including surgical and non-surgical procedures. This includes the globally top-selling transurethral resection generator, the GreenLight Laser. Endo's Specialty Products segment manufactures devices and active ingredients for critical infrastructure used in medical research and development. This unit has heavily focused on developing innovative solutions for medical challenges in recent years. Overall, Endo holds approximately 1% market share of the global pharmaceutical market. To strengthen its competitive position, the company focuses on expanding its product portfolio, increasing efficiency, and reducing costs. Endo has a strong presence in the American and European markets and is also active in emerging economies. It follows a growth strategy that emphasizes the introduction of new and innovative products to further expand its existing segments and explore new business areas. In 2020, Endo employed over 3500 employees worldwide and generated approximately $2.5 billion in revenue. The company aims to solidify its position as a leading pharmaceutical company and expand its influence in the global market. Endo International ist eines der beliebtesten Unternehmen auf Eulerpool.com.